Wani sabon karatun gwaji na asibiti na SELECT yana ƙarfafa nau'in magungunan Ozempic, dangane da semaglutide, ba da kariya ga cututtukan zuciya ga masu kiba ko masu kiba waɗanda suka rigaya ke fama da cututtukan zuciya. Sakamakon, wanda aka buga a cikin The Lancet, yana ƙarfafa cewa tasirin ya kasance bayan asarar nauyi, maɓalli mai mahimmanci don aikin asibiti.
A cikin wannan bincike, miyagun ƙwayoyi sun rage mahimmancin manyan abubuwan da ke faruwa na zuciya da jijiyoyin jini, tare da raguwa 20% a cikin ciwon zuciya, bugun jini ko mutuwar zuciyaHaɓakawa ba ta dogara da kilo nawa kowane ɗan takara ya yi hasarar ba kuma, a haƙiƙa, raguwar kewayen kugu kawai ya bayyana a kusa. kashi ɗaya bisa uku na jimlar ribar.
Abin da sabon binciken SELECT ya kawo
Zabi sun haɗa fiye da mutane 17.600 sama da shekaru 45, tare da ma'auni na jiki (BMI) ≥27 da kuma kafa cututtuka na zuciya da jijiyoyin jini, wanda aka dauka a cikin kasashe 41. Mahalarta, duk ba tare da ciwon sukari ba, sun karɓa allurar mako-mako na semaglutide ko placebo kuma an bi su fiye da shekaru biyu.
Idan aka kwatanta da placebo, semaglutide ya rage manyan abubuwan da ke faruwa na zuciya da jijiyoyin jini (MACE) ta 20%Wannan tasirin ya kasance daidai ba tare da la'akari da nauyin farko ba da kuma yawan nauyin da aka rasa a biyo baya, yana jaddada cewa kariyar Ba a bayyana shi kawai ta hanyar rasa nauyi ba.
Binciken ya raba rawar nauyi da kewayen kugu. Yayin da canje-canjen nauyi ke da ƙayyadaddun ƙima, kowane raguwa na kusan santimita 5 a kugu yana da alaƙa da raguwar kusan. 4% a cikin hadarin zuciya da jijiyoyin jini, bayanin game da 33% na amfanin jiyya; ragowar yana nuna wasu hanyoyin.
A cewar tawagar da John Deanfield (UCL) ya jagoranta, kitse na ciki yana da illa musamman ga zuciya kuma yana rage shi yana da mahimmanci, amma har yanzu akwai sauran. kashi biyu bisa uku na tasirin kariya ba tare da hanya ɗaya don bayyana shi ba. Wannan yana buɗe kofa don kai tsaye hanyoyin cututtukan zuciya na semaglutide a cikin kyallen takarda da tasoshin.
Hanyoyi masu yiwuwa fiye da ma'auni
Semaglutide shine a GLP-1 agonist mai karɓa, hanyar hormonal da ke daidaita ci da glucose na jini bayan cin abinci. Bayan sarrafa nauyi, shaidu suna nuna tasiri mai kyau akan kumburi na jijiyoyin jini, endothelial aiki da hemodynamic da lipid sigogi.
- rage kumburi: raguwa a cikin cytokines na proinflammatory wanda ke lalata arteries.
- Mafi kyawun hawan jini da lipids: tasiri mai tasiri akan tashin hankali da HDL cholesterol da LDL.
- Ayyukan endothelial mafi cancanta: tasoshin da mafi kyawun iya haɓakawa.
Ga Deanfield, waɗannan sakamakon "sake saita" hangen nesa na miyagun ƙwayoyi: ba zai zama magani kawai don asarar nauyi ba, har ma. kayan aikin kariya na zuciya da jijiyoyin jini kai tsaye a cikin marasa lafiya da kafa cuta.
Abubuwan da ke faruwa na asibiti a Spain da Turai
Kwararru a muhallinmu, kamar Antonia Delgado (Asibitin Gregorio Marañón), ya nuna cewa kewayen ciki yana nuna kitsen visceral, wanda ke da alaƙa da ciwon zuciya da bugun jini. José Luis Zamorano (Asibitin Ramón y Cajal), bayanan suna tallafawa tasirin cututtukan zuciya na kansa; kuma Cristóbal Morales (Asibitin Vithas Sevilla) yana nuna darajarta a rigakafin cututtukan zuciya a cikin marasa lafiya tare da BMI ≥27 da cututtukan zuciya.
Idan an tabbatar kuma an canza shi zuwa jagororin, semaglutide zai iya fadada nuninsa zuwa bayanan martaba masu kiba tare da babban haɗarin zuciya da jijiyoyin jini, koda kuwa ba su sami babban asarar nauyi ba. A Turai, wasu tsarin kiwon lafiya sun fara kimanta amfaninsa tare da wannan hanyar, yayin da a Spain ana ta muhawara game da yiwuwar ba da kuɗaɗen sa a yanayin rigakafin na biyu.
Tasirin lafiyar lafiyar yana da mahimmanci: cututtuka na zuciya da jijiyoyin jini sun kasance sanadin mutuwa a kasar mu. Magungunan da ke iya rage mummunan al'amura a cikin marasa lafiya tare da kafa cuta, ba tare da la'akari da nauyin da aka rasa ba, yana wakiltar dama ga rage nauyin kulawa da inganta yanayin rayuwa, kuma ana iya haɗa su da fasaha irin su a agogon da ke gano bugun zuciya.
Iyaka da taka tsantsan
SELECT bai haɗa da masu ciwon sukari ba kuma ya kasance Novo Nordisk ta ba da tallafi, mai yin maganin. Bugu da ƙari, ƙungiyar tana da ƙayyadaddun bambance-bambance-fararen maza sun fi rinjaye-don haka yana buƙata bincike ta hanyar jima'i da kabilanci da karin bayanai a wasu rukunoni.
A yanzu, tabbataccen shaida yana iyakance ga manya tare da BMI ≥27 da kafa cututtuka na zuciya da jijiyoyin jini. Ana amfani da shi a cikin mutanen da ba su da nauyi ko kuma cikin buƙatun rigakafin farko takamaiman gwaje-gwaje kafin yin la'akari da manyan canje-canjen alamomi.
Cikakken hoton da bayanan SELECT ya bari a bayyane yake: Nau'in magungunan Ozempic suna samarwa gagarumin fa'idar zuciya da jijiyoyin jini a cikin marasa lafiya ba tare da ciwon sukari ba kuma masu kiba ko kiba, kuma wannan tasirin bai dogara da adadin akan sikelin ba; da kugu yana da mahimmanci, amma bai bayyana komai ba, wanda ke nuna hanyoyin cardiometabolic cewa bincike ya riga ya fara bayyana.